Vertex claims "time to be profitable", as it assembles sales force ahead of FDA decision on telaprevir
This article was originally published in Scrip
Executive Summary
With increased investment in building out a US commercial infrastructure and higher R&D spending, it was not surprising that Vertex reported that its loss widened in 2010. The company is building up its US commercial organisation in anticipation of a US FDA decision on 23 May on its lead drug candidate, telaprevir, as a potential treatment for hepatitis C.